Blog
RSS FeedPosted by Michael Wonder on 10 Feb 2026
Painkillers and HRT therapies among drugs not being subsidised under PBS
10 February 2026 - Patients are being hit with excessive costs on a range of everyday prescription medicines because of ...
Posted by Michael Wonder on 09 Feb 2026
SMC - February 2026 decisions
9 February 2026 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 09 Feb 2026
Agenda for the March 2026 PBAC meeting (9 February 2026)
9 February 2026 - The Department of Health has published an updated agenda for the March 2026 PBAC agenda (version ...
Posted by Michael Wonder on 07 Feb 2026
Kisqali receives positive draft recommendation from Canada's Drug Agency for all eligible early breast cancer patients at high risk of recurrence
6 February 2026 - The draft recommendation for Kisqali (ribociclib tablets) from Canada's Drug Agency (CDA-AMC) supports public reimbursement for hormone ...
Posted by Michael Wonder on 05 Feb 2026
PHARMAC proposes wider access to a treatment for people with a rare blood cancer
4 February 2026 - People in New Zealand living with a rare type of blood cancer, systemic anaplastic large cell ...
Posted by Michael Wonder on 04 Feb 2026
Rezurock now reimbursed in Ontario and British Columbia for people living with chronic graft versus host disease
3 February 2026 - British Columbia and Ontario recently added Rezurock (belumosudil) to their provincial formularies for adult and pediatric patients ...
Posted by Michael Wonder on 04 Feb 2026
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer
3 February 2026 - GSK announced today that Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for ...
Posted by Michael Wonder on 02 Feb 2026
Donanemab in early Alzheimer's disease: important questions remain unanswered
30 January 2026 - For the treatment of Alzheimer's disease, it is crucial to distinguish between those with mild cognitive ...
Posted by Michael Wonder on 02 Feb 2026
Call for access to improve quality of life for thyroid cancer survivors
2 February 2026 - A TGA approved drug that prevents kidney failure in thyroid cancer survivors remains inaccessible. ...
Posted by Michael Wonder on 01 Feb 2026
Cheaper medicines to help men fight prostate cancer
1 February 2026 - From today, Australians with an aggressive form of prostate cancer will have access to cheaper medicines ...
Posted by Michael Wonder on 01 Feb 2026
New Zealand Pharmaceutical Schedule - 1 February 2026
1 February 2026 - The February 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Jan 2026
Schedule of Pharmaceutical Benefits - 1 February 2026
1 February 2026 - The February 2026 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jan 2026
Cancer patients gain new hope as Keytruda treatment recommended for subsidy under PBS
31 January 2026 - Lifesaving treatment for cancers that now costs tens of thousands of dollars is set to be cut ...
Posted by Michael Wonder on 30 Jan 2026
Recommendations made by the PBAC – December 2025 intracycle meeting
30 January 2026 - The recommendations from the December 2025 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 30 Jan 2026
Canadians wait too long for access to innovative drugs, cautions the MEI
29 January 2026 - Pharmaceutical innovation is responsible for up to 66% of the increase in the age of death ...